On CNBC’s “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, said he remains long on Apple Inc. (NASDAQ:AAPL).
Supporting his view, Wedbush analyst Dan Ives, on Tuesday, reiterated Apple with an Outperform rating and maintained a $350 price target.
Jim Lebenthal, partner at Cerity Partners, said AstraZeneca PLC (NYSE:AZN) is a high-quality pharmaceutical stock.
On the earnings front, AstraZeneca, on Feb. 10, reported fourth-quarter 2025 sales of $15.50 billion, up 4% year over year (+2% at constant currency or cc), almost in line with the consensus of $15.49 billion. The adjusted earnings were $2.12 per share, beating the consensus of $2.09.
Don’t forget to check out our premarket coverage here
Jenny Van Leeuwen Harrington, chief executive officer of Gilman Hill Asset Management, LLC, said VICI Properties Inc. (NYSE:VICI) has a 6% dividend yield.
On Feb. 2, Scotiabank analyst Nicholas Yulico downgraded VICI Properties from Sector Outperform to Sector Perform and lowered the price target from $36 to $30.
Joe Terranova, senior managing director for Virtus Investment Partners, named Ulta Beauty, Inc. (NASDAQ:ULTA) as his final trade.
According to recent news, Ulta Beauty announced on Jan. 23 its first store opening in the United Arab Emirates. The cosmetics and skincare giant said it will debut at Mall of the Emirates on Jan. 29, in partnership with Alshaya Group.
Price Action:
- Apple shares gained 3.2% to close at $263.88 on Tuesday.
- AstraZeneca shares rose 1.9% to close at $209.48 during the session.
- VICI Properties shares gained 1.9% to settle at $29.86 on Tuesday.
- Ulta Beauty shares gained 3.4% to close at $706.82 during the session.
Photo: Shutterstock
Recent Comments